Exchange Traded Concepts LLC Raises Stock Holdings in Novo Nordisk A/S $NVO

Exchange Traded Concepts LLC boosted its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 59.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 171,668 shares of the company’s stock after purchasing an additional 64,199 shares during the quarter. Exchange Traded Concepts LLC’s holdings in Novo Nordisk A/S were worth $8,734,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently added to or reduced their stakes in NVO. Capital International Investors lifted its position in shares of Novo Nordisk A/S by 52.4% during the third quarter. Capital International Investors now owns 17,713,424 shares of the company’s stock valued at $982,969,000 after buying an additional 6,092,192 shares during the last quarter. Franklin Resources Inc. grew its position in shares of Novo Nordisk A/S by 4,190.8% in the 3rd quarter. Franklin Resources Inc. now owns 13,984,789 shares of the company’s stock worth $776,016,000 after buying an additional 13,658,867 shares during the last quarter. Folketrygdfondet raised its stake in shares of Novo Nordisk A/S by 1.2% during the 3rd quarter. Folketrygdfondet now owns 10,211,913 shares of the company’s stock worth $566,659,000 after acquiring an additional 117,370 shares in the last quarter. State Street Corp raised its stake in shares of Novo Nordisk A/S by 1.0% during the 3rd quarter. State Street Corp now owns 6,106,836 shares of the company’s stock worth $340,125,000 after acquiring an additional 59,153 shares in the last quarter. Finally, Boston Partners purchased a new stake in Novo Nordisk A/S during the third quarter valued at approximately $310,199,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S News Summary

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: FDA approves Awiqli (insulin icodec‑abae), the first once‑weekly basal insulin for adults with type 2 diabetes — expands treatment choices, may improve adherence vs daily basal insulin and supports a U.S. launch in the second half of 2026. US FDA approves Novo’s insulin injection for type 2 diabetes
• Positive Sentiment: Corporate governance/market strategy bolstered by appointment of Mars CEO Poul Weihrauch as a board observer — intended to strengthen Novo’s positioning and commercial insights in the competitive U.S. obesity market. Novo Nordisk appoints Mars CEO as board observer
• Neutral Sentiment: Filed updated Articles of Association and capital‑increase mandate — routine corporate housekeeping that can enable share issuance or compensation plans but has no immediate earnings impact. Articles of Association for Novo Nordisk A/S 2026
• Neutral Sentiment: Mixed analyst coverage: Wolfe Research started coverage with a “peer perform” rating and some brokers give neutral takes on the pipeline — underscores divergent views on growth sustainability vs valuation.
• Neutral Sentiment: Pipeline commentary: promising signals for next‑generation candidates (e.g., UBT251 triple‑agonist) but analysts flag that new oral drug trends and incremental data so far are not yet transformative. GLP‑1 pipeline shows promise but oral drug trends give analysts pause
• Negative Sentiment: Bernstein initiated coverage with an Underperform rating and a low price target, warning the company’s earnings downgrade cycle may not be over — a clear near‑term headwind for sentiment and the stock. Bernstein initiates coverage with Underperform
• Negative Sentiment: Recent headlines and analyst notes have coincided with share weakness and short‑term selling — valuation concerns (forward P/E in the low double digits vs peers) and profit‑taking after prior rallies are weighting the stock. Stock slides as market rises

Novo Nordisk A/S Stock Performance

Shares of Novo Nordisk A/S stock opened at $36.01 on Monday. The company has a 50 day moving average price of $45.92 and a 200 day moving average price of $50.42. The firm has a market capitalization of $160.78 billion, a P/E ratio of 10.38, a PEG ratio of 8.52 and a beta of 0.74. The company has a quick ratio of 0.57, a current ratio of 0.80 and a debt-to-equity ratio of 0.61. Novo Nordisk A/S has a 52 week low of $35.85 and a 52 week high of $81.44.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share for the quarter, topping the consensus estimate of $0.90 by $0.11. The company had revenue of $12.43 billion for the quarter, compared to the consensus estimate of $11.97 billion. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. Sell-side analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Announces Dividend

The business also recently disclosed a dividend, which will be paid on Wednesday, April 8th. Stockholders of record on Monday, March 30th will be issued a dividend of $1.2751 per share. The ex-dividend date of this dividend is Monday, March 30th. This represents a dividend yield of 708.0%. Novo Nordisk A/S’s payout ratio is 23.63%.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the stock. Weiss Ratings downgraded shares of Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, March 18th. TD Cowen downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $42.00 price target on the stock. in a research report on Tuesday, March 10th. Wolfe Research began coverage on Novo Nordisk A/S in a report on Thursday. They set a “peer perform” rating for the company. Morgan Stanley raised Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $40.00 price objective for the company in a research report on Tuesday, March 3rd. Finally, The Goldman Sachs Group restated a “neutral” rating and set a $41.00 target price (down from $63.00) on shares of Novo Nordisk A/S in a research note on Monday, March 2nd. Four investment analysts have rated the stock with a Buy rating, nineteen have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Novo Nordisk A/S has a consensus rating of “Hold” and an average target price of $65.56.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.